新闻情绪
正面
- CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
- CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
负面
AIStockmoo 评分
| 价值 30% | 0.7 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力强。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 时机 30% | -3.4 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 近期出现看涨反转形态:倒锤子线。 参考 | |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.3 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | 3.5 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+5.68%的股份:99家增持,90家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-11.4%,回补天数8.4天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | -0.06 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | CorMedix Inc. | 混合的 | 看跌 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| CRMD | - | - | - | 0.800 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| MLTX | - | - | - | 2.79 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.08% |
| 机构持股比例 | 34.20% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 64.78%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 99 | 7,583,312 |
| 减持 | 90 | 3,469,708 |
| 新建仓 | 31 | 1,461,982 |
| 清仓 | 20 | 1,030,741 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 14,205,973 | 8.4 |
| 15 Oct 2026 | 14,665,697 | 12.7 |
| 30 Sep 2026 | 15,422,728 | 18.9 |
| 15 Sep 2026 | 16,202,272 | 18.5 |
| 31 Aug 2026 | 16,032,112 | 13.0 |
| 14 Aug 2026 | 17,149,908 | 11.1 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
7 正面
3 负面
4 中性
| 日期 | 类型 | 细节 |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition t… |
| 13 Nov 2026 | Yahoo Finance |
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook. |
| 12 Nov 2026 | Yahoo Finance |
CorMedix Inc. Q3 2026 Earnings Call Summary
Moby summary of CorMedix Inc.'s Q3 2026 earnings call… |
| 12 Nov 2026 | Yahoo Finance |
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
Heron deal and DefenCath reimbursement shifts drive the quarter. |
| 12 Nov 2026 | Yahoo Finance |
What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix (NASDAQ:CRMD) reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment. Revenue fell to $54.5 million fr… |
| 12 Nov 2026 | Yahoo Finance |
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 12 Nov 2026 | Yahoo Finance |
CorMedix: Q3 Earnings Snapshot
(CRMD) on Thursday reported a loss of $14.On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 19 cents. |
| 12 Nov 2026 | Yahoo Finance |
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for… |
| 10 Nov 2026 | Yahoo Finance |
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies. |
| 10 Nov 2026 | Yahoo Finance |
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
CorMedix (NASDAQ:CRMD) has agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings. CorMedix will pay $145 million in cash and approximately 14.6 m… |
| 09 Nov 2026 | Yahoo Finance |
CorMedix stock gains as Heron deal adds four products
Investing.com -- CorMedix Inc (NASDAQ:CRMD) shares rose 4.5% in premarket trading Monday after the company announced it will acquire substantially all assets of Heron Therapeutics Inc (NASDAQ:HRTX) for approximately $222.6 million. Heron stock surged 45% on the news. |
| 09 Nov 2026 | Yahoo Finance |
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common… |
| 06 Nov 2026 | Yahoo Finance |
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call… |
| 04 Nov 2026 | Yahoo Finance |
Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 02 Nov 2026 | Yahoo Finance |
CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
CorMedix Therapeutics (NASDAQ:CRMD) has maintained its full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, according to a business update released on November 2. The pharmaceutical… |
| 02 Nov 2026 | Yahoo Finance |
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance. Business Updates CorMedix announces… |
| 显示更多 | ||
投资组合